Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | MPO | P05164 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | BLM | P54132 | 1/20 | 0.68 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.68 |
| ▸ | ECE1 | P42892 | 7/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30862463 | 1.00 | ACE (0.69) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL30862452 | 1.00 | ACE (0.69) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL30862460 | 1.00 | ACE (0.69) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL30862455 | 1.00 | ACE (0.69) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL9868128 | 1.00 | ACE (0.69) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL30862445 | 1.00 | ACE (0.69) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL30862448 | 1.00 | ACE (0.69) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL29531119 | 1.00 | ACE (0.69) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL30862461 | 1.00 | ACE (0.69) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL30862439 | 1.00 | ACE (0.69) | ACEKDM4EMEN1LMNAMPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144842-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TRYPTOPHAN AND PHYLLOKININ DERIVATIVE FOR USE IN TREATING PSYCHIATRIC AND PSYCHOLOGICAL CONDITIONS | TEMPLE OTORONGO LLC (US) | 2026-05-28 | — | — | US | claimed |
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260114475-A1 | ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME | MARS, INCORPORATED (US) | 2026-04-30 | — | — | US | disclosed |
| US-20250345410-A1 | VACCINATION IN NEWBORNS AND INFANTS | CureVac SE (DE) | 2025-11-13 | — | — | US | disclosed |
| US-20250345411-A1 | VACCINATION IN NEWBORNS AND INFANTS | CureVac SE (DE) | 2025-11-13 | — | — | US | disclosed |
| US-12390520-B2 | Vaccination in newborns and infants | Cure Vac SE (DE) | 2025-08-19 | — | — | US | disclosed |
| EP-4593631-A1 | ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME | Mars, Incorporated (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20240390478-A1 | VACCINATION IN ELDERLY PATIENTS | CureVac SE (DE) | 2024-11-28 | — | — | US | disclosed |
| US-12036277-B2 | Vaccination with mRNA-coded antigens | CureVac SE (DE) | 2024-07-16 | — | — | US | disclosed |
| US-20240197857-A1 | VACCINATION WITH mRNA-CODED ANTIGENS | CureVac SE (DE) | 2024-06-20 | — | — | US | disclosed |
| US-20230302146-A1 | HYBRID CARRIERS FOR NUCLEIC ACID CARGO | CureVac SE (DE) | 2023-09-28 | — | — | US | disclosed |
| US-20230285594-A1 | COMPLEXATION OF NUCLEIC ACIDS WITH DISULFIDE-CROSSLINKED CATIONIC COMPONENTS FOR TRANSFECTION AND IMMUNOSTIMULATION | CureVac SE (DE) | 2023-09-14 | — | — | US | disclosed |
| CN-116716324-A | Alkane degradation gene, protein and application thereof | 山东省科学院生态研究所(山东省科学院中日友好生物技术研究中心) | 2023-09-08 | — | — | CN | disclosed |
| US-20230233662-A1 | VACCINATION IN NEWBORNS AND INFANTS | CureVac SE (DE) | 2023-07-27 | — | — | US | disclosed |
| US-11672856-B2 | Vaccination in newborns and infants | CureVac SE (DE) | 2023-06-13 | — | — | US | disclosed |
| CN-109475640-B | Mixed carrier for nucleic acid carried article | 库瑞瓦格欧洲公司 | 2023-03-10 | — | — | CN | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
| US-11478552-B2 | Hybrid carriers for nucleic acid cargo | CUREVAC AG (DE) | 2022-10-25 | — | — | US | disclosed |
| CN-114605496-A | Polypeptide and application thereof, antibacterial drug and preparation method thereof | 华中科技大学 | 2022-06-10 | — | — | CN | disclosed |
| EP-3206704-B1 | PEPTIDES HAVING ANTI-INFLAMMATORY PROPERTIES | RIPTIDE BIOSCIENCE INC (US) | 2022-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11478552-B2 | Hybrid carriers for nucleic acid cargo | HNRNPH1, HNRNPH3, SNRPE | ACE 4699/4885KDM4E 4808/4885MEN1 1579/4885 |
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | ACE 1190/4885KDM4E 1136/4885MEN1 1217/4885 |
| US-20260144842-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TRYPTOPHAN AND PHYLLOKININ DERIVATIVE FOR USE IN TREATING PSYCHIATRIC AND PSYCHOLOGICAL CONDITIONS | OPRK1, TPH1, HTR3C | ACE 4214/4885KDM4E 4515/4885MEN1 3812/4885 |
| US-20250345410-A1 | VACCINATION IN NEWBORNS AND INFANTS | HLA-DRB1, TLR3, TLR9 | ACE 4227/4885KDM4E 3834/4885MEN1 1881/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | ACE 486/4885KDM4E 4697/4885MEN1 1147/4885 |
| US-20230302146-A1 | HYBRID CARRIERS FOR NUCLEIC ACID CARGO | HNRNPH1, HNRNPH3, SNRPE | ACE 4699/4885KDM4E 4808/4885MEN1 1579/4885 |
| US-20260114475-A1 | ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME | PIGS, TAS2R13, CEL | ACE 2100/4885KDM4E 984/4885MEN1 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.